Abstract

Anti-tuberculosis drug induced liver injury (ATDILI) ranks the first in all kinds of drug-induced liver injuries. ATDILI causes not only economic loss of public health system and patients, but also mental burden of patients, and often leads to treatment interruption or drug resistance. To investigate the clinical characteristics and predisposing factors of ATDILI, the clinical characteristics of 2457 hospital-admitted cases treated with anti-tuberculosis (TB) drugs during 2005 and 2009 and their correlative factors were retrospectively analyzed. The incidence of ATDILI among 2457 TB patients who were treated for the first time was 10.9% (267/2457), that is 13.6% (148/1085) in female and 8.7% (119/1372) in male. Female TB patients were more prone to have ATDILI as compared to male TB patients (P<0.05). The incidence of ATDILI in TB patients who were not treated with liver protectants (13.8%, 80/581) was significantly higher than that in patients who were treated with liver protectants (10.0%, 187/1876, P<0.05). 13.2% (139/1050) patients treated with isoniazid (H), rifampin (R), and pyrazinamide (Z)/ethambutol (E) (HRZ/E) regime had ATDILI, which was significantly higher than that in TB patients treated with HRE (9.1%, 128/1407, P<0.05). Susceptible patients of ATDILI should take appropriate preventive measures to avoid the occurrence of drug-induced liver injury.

Key words: Liver injury, anti-tuberculosis drugs, clinical characteristics, predisposing factor.